Announcements

Nano4 Global was awarded with SME Instrument Phase 2 grant

Nano4 Global has been selected for the SME Instrument Phase 2 initiative of Horizon 2020, a very competitive initiative. It was one of the few companies from life science field to be selected.

Innovation for gene therapy

MagicCELLGene aims at developing a disruptive new technology DNA/RNAi transfection - magiccellgene.wixsite.com/magiccellgene. MagicCELLGene focus on the site directed magnetic hyperthermia that creates focal hotspots on the cell membrane to allow the entry of therapeutic nucleic acids, with potential clinical applications in cell-based gene therapy.

Magnetic nanoparticles for improved diagnsotics of HIV/TB wins the Gilead Genese Prize

The Gilead Genese Prize will be instrumental for the construction of the capture MNPs and validation of molecular assays on patient samples. This endeavor is only possible due to the long-lasting collaboration between IHMT-NOVA TB Group lead by Miguel Viveiros and João Piedade for HIV and the Nanomedicine Group lead by Pedro V. Baptista at UCIBIO, Dept of Life Sciences, FCT-NOVA.

Project RADetect - One Platform- Multiple biomarker detection of Rheumatoid Arthritis“.

RA detect has developed a simple yet robust detection platfromfor RF that hopes to see validation in the clinics in a near future

Gold nanoparticles for the control of blood vessels growth


Scientists at UCIBIO, FCT, Universidade NOVA de Lisboa have demonstrated for the first time the potential use of smart nanomaterials for the effective modulation of angiogenesis in vivo.

EXPO FCT 2016

This was the Nanotheragnostics Table: